Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Affinity and Avidity01:41

Affinity and Avidity

35.4K
Overview
35.4K
Septins01:19

Septins

1.6K
Septins are protein filaments forming the cytoskeleton along with the microtubules, microfilaments, intermediate filaments, and other accessory proteins. In 1971 while studying the cell division cycle in mutant Saccharomyces cerevisiae Harwell et al. first identified the septin-related genes playing a crucial role in yeast cytokinesis. Fluorescence microscopy revealed that these proteins localize at the budding neck as rings. These ring-like proteins were then named Septins by John Pringle, and...
1.6K
Midrange01:07

Midrange

2.8K
A somewhat easy to compute quantitative estimate of a data set’s central tendency is its midrange, which is defined as the mean of the minimum and maximum values of an ordered data set.
Simply put, the midrange is half of the data set’s range. Similar to the mean, the midrange is sensitive to the extreme values and hence the prospective outliers. However, unlike the mean, the midrange is not sensitive to all the values of the data set that lie in the middle. Thus, it is prone to...
2.8K
Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)01:15

Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)

1.2K
Insensitive Nuclei Enhanced by Polarization Transfer (INEPT) is an advanced Nuclear Magnetic Resonance (NMR) technique specifically designed to detect and enhance the signals of low-abundance nuclei, such as carbon-13 and nitrogen-15, in small molecules. The fundamental principle behind INEPT is the transfer of polarization from a more abundant and highly polarizable nucleus, typically hydrogen-1, to the low-abundance nucleus of interest. This process effectively boosts the NMR signal of the...
1.2K
Evolution of New Traits in Microbes01:24

Evolution of New Traits in Microbes

199
Microorganisms evolve rapidly due to their large population sizes and short generation times, often exhibiting measurable changes within days under laboratory conditions. Natural selection acts on standing genetic variation, enabling the retention and amplification of beneficial traits that confer fitness advantages in changing environments.Adaptive Pigment Regulation in RhodobacterIn Rhodobacter, a genus of purple non-sulfur bacteria, light-harvesting pigments such as bacteriochlorophyll and...
199
iChip01:24

iChip

105
The cultivation of environmental microorganisms has long been hindered by the inability to replicate complex native conditions in vitro. The isolation chip (iChip) addresses this limitation by facilitating the growth of previously uncultivable microorganisms through in situ incubation. Designed for high-throughput microbial cultivation, the iChip comprises hundreds of microchambers, each capable of housing a single microbial cell. These microchambers are loaded with a mixture of molten agar and...
105

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

JAMA oncology·2026
Same author

Real-World Assessment of Prophylactic Anakinra on Neurotoxicity and Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory B-Cell Lymphoma: An Inverse Probability of Treatment Weighting Analysis.

Transplantation and cellular therapy·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026
Same author

Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients.

Blood advances·2026
Same author

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Blood advances·2026
Same author

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Blood advances·2026

Related Experiment Video

Updated: May 2, 2026

Stiffness Measurement of Soft Silicone Substrates for Mechanobiology Studies Using a Widefield Fluorescence Microscope
07:02

Stiffness Measurement of Soft Silicone Substrates for Mechanobiology Studies Using a Widefield Fluorescence Microscope

Published on: July 3, 2018

7.3K

IMiDs New and Old.

Samuel Yamshon1, Jia Ruan2

  • 1Division of Hematology and Medical Oncology, Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, 1305 York Avenue, New York, NY, 10021, USA.

Current Hematologic Malignancy Reports
|July 15, 2019
PubMed
Summary
This summary is machine-generated.

Immunomodulatory drugs (IMiDs) show promise in treating non-Hodgkin lymphoma (NHL) subtypes. Lenalidomide is approved for specific NHLs and effective in various combinations, guiding future therapeutic strategies.

Keywords:
AvadomideImmunomodulationLenalidomideLymphomaThalidomide

More Related Videos

A Purification and In Vitro Activity Assay for a pppGpp Synthetase from Clostridium difficile
09:53

A Purification and In Vitro Activity Assay for a pppGpp Synthetase from Clostridium difficile

Published on: November 3, 2018

8.9K
Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling
11:19

Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling

Published on: November 17, 2019

17.0K

Related Experiment Videos

Last Updated: May 2, 2026

Stiffness Measurement of Soft Silicone Substrates for Mechanobiology Studies Using a Widefield Fluorescence Microscope
07:02

Stiffness Measurement of Soft Silicone Substrates for Mechanobiology Studies Using a Widefield Fluorescence Microscope

Published on: July 3, 2018

7.3K
A Purification and In Vitro Activity Assay for a pppGpp Synthetase from Clostridium difficile
09:53

A Purification and In Vitro Activity Assay for a pppGpp Synthetase from Clostridium difficile

Published on: November 3, 2018

8.9K
Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling
11:19

Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling

Published on: November 17, 2019

17.0K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Immunomodulatory drugs (IMiDs) possess immunomodulatory, anti-angiogenic, and direct anti-cancer effects.
  • Lenalidomide, an improved second-generation IMiD, offers enhanced efficacy and a better side effect profile than thalidomide.
  • CC-122 represents a next-generation cereblon modulator in early clinical investigation.

Purpose of the Study:

  • To review the clinical development and application of IMiDs in non-Hodgkin lymphoma (NHL) subtypes.
  • To focus on lenalidomide's role and discuss management of its common side effects.
  • To explore the potential of IMiDs in future combinatorial therapies for NHL.

Main Methods:

  • Review of current clinical trial data and literature on IMiDs in NHL.
  • Analysis of lenalidomide's efficacy as a single agent and in combination regimens.
  • Discussion of emerging therapeutic strategies and biomarker research.

Main Results:

  • Lenalidomide is FDA-approved for relapsed/refractory mantle cell lymphoma and used in combination for follicular and marginal zone lymphomas.
  • Clinical trials demonstrate lenalidomide's promise in both upfront and relapsed/refractory aggressive and indolent NHL.
  • IMiDs are emerging as key components for combination therapies, including with antibodies, chemotherapy, and immunotherapies.

Conclusions:

  • IMiDs, particularly lenalidomide, are integral to current and future NHL treatment paradigms.
  • Combinatorial strategies involving IMiDs with novel agents and immunotherapies hold significant therapeutic potential.
  • Identifying treatment- and disease-specific biomarkers is crucial for optimizing IMiD application and guiding future research.